Found 297 articles for: "biologics"
Effect of Topical Human Platelet Extract (HPE) for Facial Skin Rejuvenation: A Histological Study of Collagen and Elastin
September 2024 | Volume 23 | Issue 9 | Original Article | 735 | Copyright © September 2024
Background: Regenerative aesthetics has garnered significant attention. In this toolkit, exosomes are small extracellular vesicles derived from various sources such as platelets....
Read MoreINDIVIDUAL ARTICLE: NECOM 4: Algorithm Integrating Skincare for the Management of Immunotherapy-Related Cutaneous Adverse Events for Cancer Patients and Survivors
August 2024 | Volume 23 | Issue 8 | Supplement Individual Articles | 85411s3 | Copyright © August 2024
Background: In the Nordic European Countries, cancer is the leading cause of death. The last decade has brought revolutionizing cancer treatments including immune checkpoint inhi...
Read MoreTildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
August 2024 | Volume 23 | Issue 8 | Original Article | 612 | Copyright © August 2024
Background: Tildrakizumab is a humanized anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes real...
Read MoreSafety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
August 2024 | Volume 23 | Issue 8 | Original Article | 592 | Copyright © August 2024
Background: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target bot...
Read MoreApplications of Bruton Tyrosine Kinase Inhibitors in Dermatology
August 2024 | Volume 23 | Issue 8 | Features | 697 | Copyright © August 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas
August 2024 | Volume 23 | Issue 8 | Original Article | 619 | Copyright © August 2024
Background: Psoriasis involving challenging body areas, such as the scalp, face, palmoplantar surfaces, or nails, can be challenging to treat and negatively affects patient outco...
Read MoreThe Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis: A Retrospective, Multicenter, Observational Study
August 2024 | Volume 23 | Issue 8 | Editorials | e169 | Copyright © August 2024
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study
August 2024 | Volume 23 | Issue 8 | Original Article | 632 | Copyright © August 2024
Background: Guselkumab is a monoclonal antibody approved for treating moderate-to-severe plaque psoriasis. Long-term data on the effectiveness and safety of guselkumab in a real-...
Read MoreRapid Remission of Plaque Psoriasis With Bimekizumab Treatment
August 2024 | Volume 23 | Issue 8 | Features | 694 | Copyright © August 2024
Bimekizumab is a novel humanized bispecific monoclonal immunoglobulin G1 (IgG1) antibody that dually inhibits both IL-17A and IL-17F. Investigation of the pivotal role of IL-17A, and more recentl...
Read MorePalmoplantar Pustulosis: Therapy Update
August 2024 | Volume 23 | Issue 8 | Original Article | 626 | Copyright © August 2024
Palmoplantar pustulosis is a variant of psoriasis and a chronic skin disorder in which pruritic pustular eruptions appear on the palms and soles. It is thought to arise from a variety of genetic ...
Read MoreTreatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients
June 2024 | Volume 23 | Issue 6 | Editorials | e144 | Copyright © June 2024
Bullous pemphigoid is often difficult to treat with the limited therapies available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. W...
Read MoreEfficacy and Safety of Micronized Isotretinoin Administered Once Daily Without Food in Patients With Recalcitrant Nodular Acne
June 2024 | Volume 23 | Issue 6 | Original Article | 423 | Copyright © June 2024
Introduction: Micronized isotretinoin 0.4 to 0.8 mg/kg/day administered in 2 divided doses with or without meals is approved for the treatment of severe nodular acne in patients ...
Read MoreDermatologists' Perspectives on Biosimilars
April 2024 | Volume 23 | Issue 4 | Features | 277 | Copyright © April 2024
Background: Biosimilars are biologic agents the Food and Drug Administration (FDA) has deemed to have no clinical difference from their reference biologics. In dermatology, biosi...
Read MoreFirst Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis
March 2024 | Volume 23 | Issue 3 | Case Reports | 192 | Copyright © March 2024
Plaque psoriasis is a chronic, immune-mediated, cutaneous, and systemic inflammatory dermatosis. Its pathogenesis involves the dysregulation of the interleukin (IL)-23/IL-17 signaling pathway. Th...
Read MoreOutcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis
February 2024 | Volume 23 | Issue 2 | Original Article | 17 | Copyright © February 2024
Background: Biologics have shown promising outcomes in psoriasis clinical trials. However, there is a paucity of data exploring the potential differences in outcomes between self...
Read MoreA New Tool to Improve Communication Between Hidradenitis Suppurativa Patients and Health Care Providers
February 2024 | Volume 23 | Issue 2 | Features | 105 | Copyright © February 2024
Background: Hidradenitis suppurativa (HS) patients tend to experience diagnosis delay, misdiagnosis, and embarrassment due to their condition. To address these issues, the Intern...
Read MoreImplicit Bias and Clinical Decision Making in Psoriasis Management Among Dermatology Residents: A Feasibility Study
February 2024 | Volume 23 | Issue 2 | Editorials | e73 | Copyright © February 2024
Psoriasis and Palmoplantar Pustulosis Following Pembrolizumab Therapy Successfully Treated With Topical Tapinarof Cream 1%
February 2024 | Volume 23 | Issue 2 | Case Reports | 103 | Copyright © February 2024
Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis
February 2024 | Volume 23 | Issue 2 | Original Article | 74 | Copyright © February 2024
Early response to treatment with biologics, defined as Psoriasis Area and Severity Index (PASI) of 2 or less six months after initiation of therapy, seems to be associated with more stable psoria...
Read MoreTargeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis
February 2024 | Volume 23 | Issue 2 | Original Article | 23 | Copyright © February 2024
Media and other results for: "biologics"
Psoriasis: Images Page
AD Treatment – The Future Landscape Blog Post
AD Treatment – The Future Landscape Blog Post